ChromaDex announces findings from study on proprietary Niagen ingredient

ChromaDex announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led by Dr. Eija Pirinen and Dr. Kirsi Pietilainen. The clinical trial was part of the ChromaDex External Research Program and investigated the company’s proprietary Niagen ingredient in 20 BMI-discordant identical twin pairs. Results of the study showcase that Nicotinamide Riboside, NR, supplementation improved muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition. This is the first published and peer-reviewed clinical study demonstrating an increase in mitochondrial biogenesis following NR supplementation in humans and is consistent with a CERP preclinical study published in Cell Reports, demonstrating NR increased mitochondrial biogenesis in neuronal cells. Additionally at five months, this clinical study marks a milestone as the longest published NR supplementation study to date. "While previous preclinical research has demonstrated that increasing NAD+ through precursor supplementation improves the quality and quantity of muscle stem cells, promotes muscle function, increases mitochondrial health and respiration, and has therapeutic effects in mitochondrial and muscle disorders, many of these benefits have yet to be translated in human clinical studies," said Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. "This study marks an important milestone in research between NR supplementation and mitochondrial biogenesis."